• HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US
  • HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US

Pyrotinib could be the choice of drug in chemotherapy treated HER2-mutant NSCLC patients

October 8, 2020
-
News
-
Posted by seoaccount medivisual
small-lung-cancer-admac

In China, a study depicted that in patients with HER2 (human epidermal growth factor receptor-2)-mutated advanced NSCLC (non-small cell lung cancer), pyrotinib 400 mg daily may be given to patients who had received at least one prior platinum-based chemotherapy. Prophylactic loperamide may be given to avoid diarrhea, the most frequent noxious event occurring due to pyrotinib.

This phase II, multicentre, open-label, single-arm trial investigated the safety and efficacy of pyrotinib (oral, irreversible, pan-ErbB tyrosine kinase inhibitor) for managing HER1, HER2, and HER4 in patients with advanced NSCLC harboring HER2 mutations, who were previously treated with platinum-based chemotherapy for advanced/metastatic disease.

For managing HER2-positive advanced breast cancer, a combination of pyrotinib and capecitabine is approved in China. In the patient-derived HER2-mutated lung cancer xenograft model, a previous study depicted a more promising anti-tumor activity of pyrotinib than afatinib or T-DM1 (Trastuzumab emtansine- the combination of trastuzumab and a chemotherapy drug called DM1).

The ORR (objective response rate) per IRC (independent review committee) was the primary endpoint.
Pyrotinib was administered to 60 patients. At baseline, 58 patients (96.7%) were found to have stage IV disease; 25 patients (41.7%) were treated with at least two lines of prior chemotherapy. The IRC-assessed ORR was found to be 30.0% as of data cut-off on 20 June 2019.

A good ORR was illustrated by all subgroups of patients with different types of HER2 mutations. The ORRs demonstrated similarity between patients with and without brain metastases as shown in the following table:

Patients with brain metastases

Patients without brain metastases

ORRs

25%

31.3%

The median progression-free and overall survival, and the median duration of response are shown in the following table:

Median duration of response

6.9 months

Median overall survival

14.4 months

Median progression-free survival

6.9 months per IRC

In 28.3% of participants, treatment-emergent noxious events of grade 3 or 4 were witnessed. The most common adverse effect was diarrhea (20%; all grade 3). There was no mortality related to treatment.

Due to the paucity of a control arm and the small sample size of patients with a missense point mutation in HER2, the clinical benefit of different subtypes in HER2 mutations could not be suitably compared. A global, randomized phase III, a multicentre trial is being planned and will be soon started.
Thus, in chemotherapy-treated patients with HER2-mutant NSCLC, pyrotinib as a single agent illustrated favorable anti-tumor effect and an acceptable safety profile.

Source

ESMO

Link:

https://www.esmo.org/oncology-news/pyrotinib-in-her2-mutated-advanced-nsclc-previously-treated-with-chemotherapy

[Last accessed on: 14 July, 2020]

Original title of the article

PYROTINIB IN HER2-MUTATED ADVANCED NSCLC PREVIOUSLY TREATED WITH CHEMOTHERAPY
← PREVIOUS POST
Black Cumin: A Food Additive With Potent Chemoprotective Properties
NEXT POST →
Clove: A valuable spice effective for cancer prevention

Related News

Other posts that you should not miss.
Ellagic-acid-Cancer-fighting-food-ingredient-admac

Ellagic acid: Cancer-fighting food ingredient

July 15, 2020
-
News

Worldwide, cancer is a major cause of death. In recent years, numerous plant-derived compounds have gained attention as alternative cancer remedies for improving the prevention and treatment of …

Read More →
Posted by seoaccount medivisual
5 MIN READ
Lurbinectedin-receives-FDA-approval-admac

Lurbinectedin receives FDA-approval to treat metastatic SCLC

August 7, 2020
-
News

For adult patients with metastatic SCLC (small cell lung cancer) with disease progression on or after platinum-based chemotherapy, lurbinectedin (ZEPZELCA, Pharma Mar S.A.) received FDA (Food and Drug …

Read More →
Posted by seoaccount medivisual
1 MIN READ
vegetable-and-fruits-color-on-colorectal-cancer-admac

Influence of Vegetable and Fruits Color on Colorectal Cancer

November 20, 2020
-
News

In the prevention and lowering the various types of cancers, vegetables and fruits play a very essential role. Not only in preventing cancer, but also in preventing other …

Read More →
Posted by admin
3 MIN READ
Please speak to us:
  • Phone:+91 172 2565161 , +91 172 2565162
  • Email : admac@admacinternational.com
Admac House
SCO 84, Sector 5,
Panchkula (Haryana)
134112 INDIA.
Our aim

At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.

All Rights Reserved. 2016
Powered  by: Admac Oncology
Pyrotinib could be the drug in chemotherapy treated HER2-mutant NSCLC patients